Skip to main content
. 2017 Nov 1;131(4):408–416. doi: 10.1182/blood-2017-08-801985

Table 1.

Demographic and disease characteristics HPC mutation burden cohort

Characteristic Normal (N = 6) SCN (N = 11) SDS (N = 2)
Age, y
 Mean ± SD 17.7 ± 4.4 16.6 ± 7.9 7.0 ± 7.1
 Median (range) 20 (9-20) 15.5 (6-36) 7.0 (2-12)
Female sex, n (%) 2 (33.3) 5 (45.4) 1 (50)
G-CSF treatment, n (%)* 0 (0) 10 (100) 0 (0)
ANC per mm3
 Mean ± SD na 62 ± 99 1170 ± 1198
 Median (range) na 0 (0-300) 1170 (330-2020)
ELANE mutation, n (%) na 10 (100) na
SBDS mutation, n (%) na na 2 (100)

ANC obtained prior to G-CSF therapy is shown. Percentage of patients with germ line heterozygous ELANE or biallelic SBDS mutations is shown.

na, not available; SD, standard deviation.

*

Data not available for 1 patient with SCN.

Data not available for 2 patients with SCN.

Data not available for 1 patient with SCN.